Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 17, 2007. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the GlaxoSmithKline Performance Share Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share plan transactions. The only financial data points provided are the transaction prices for the notional re-investment of dividends:
- Ordinary Shares: GBP 14.33 per share
- Ordinary Share ADRs: $57.07 per ADR
Material Changes
The filing details an increase in notional interests in Ordinary Shares and ADRs for various executives following the notional re-investment of the dividend paid to shareholders on April 12, 2007. No material changes to the company's financial position or operations are reported in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It notes that notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings that vest following the end of the relevant three-year measurement period.
Important Facts for Investors to Verify
- The dividend payment date was April 12, 2007.
- Transactions were notified in accordance with Disclosure Rules 3.1.4R(1)(a) and 3.1.4R(1)(b).
- Specific notional share increases were recorded for 14 named individuals, including Dr. JP Garnier and Mr. A P Witty.
- Vesting of these notional holdings is contingent upon the end of a three-year measurement period.